Key facts
- This page summarizes Jonathan Rubin's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
- 9 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 24 Feb 2025, 20:20.
Jonathan Rubin - 21 Feb 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Reporting relationship
- SVP, Chief Medical Officer
- Issuer ticker
- SUPN
- Reported as of
- 21 Feb 2025
- Net transaction value
- -$36,292
- SEC form
- 4
- Accepted by SEC
- 24 Feb 2025, 20:20:14 UTC
- Prior SEC filing
- 21 Feb 2025
- Next SEC filing
- 05 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Timothy C. Dec, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Rubin filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 24 Feb 2025.
Change
- Previous filing in this sequence was filed on 21 Feb 2025.
- Current net transaction value: -$36,292.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SUPN
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +1,875
- Change %
- +27%
- Price
- $0.000000
- Shares after
- 8,780
- Date
- 21 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
SUPN
transaction
Common Stock
Sale
- Transaction value
- $36,292
- Shares
- -927
- Change %
- -11%
- Price
- $39.15
- Shares after
- 7,853
- Date
- 21 Feb 2025
- Ownership
- Direct
- Footnotes
- F2
SUPN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +750
- Change %
- +9.6%
- Price
- $0.000000
- Shares after
- 8,603
- Date
- 22 Feb 2025
- Ownership
- Direct
SUPN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,250
- Change %
- +15%
- Price
- $0.000000
- Shares after
- 9,853
- Date
- 22 Feb 2025
- Ownership
- Direct
SUPN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,250
- Change %
- +13%
- Price
- $0.000000
- Shares after
- 11,103
- Date
- 23 Feb 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SUPN
transaction
Derivative
Performance Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,875
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 21 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,875
- Exercise price
- $0.000000
- Footnotes
- F3
SUPN
transaction
Derivative
Restricted Stock Unit
Disposed to Issuer
- Transaction value
- $0
- Shares
- -750
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 750
- Date
- 22 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 750
- Exercise price
- Footnotes
- F4, F5
SUPN
transaction
Derivative
Restricted Stock Unit
Disposed to Issuer
- Transaction value
- $0
- Shares
- -1,250
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 3,750
- Date
- 22 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,250
- Exercise price
- Footnotes
- F4, F6
SUPN
transaction
Derivative
Restricted Stock Unit
Disposed to Issuer
- Transaction value
- $0
- Shares
- -1,250
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 2,500
- Date
- 23 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,250
- Exercise price
- Footnotes
- F4, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024.
Footnote F2
Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
Footnote F3
On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.
Footnote F4
Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
Footnote F5
These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023.
Footnote F6
These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
Footnote F7
These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.